Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients With Chronic Inducible Urticaria (Part B)

NCT07181369 is registered in ClinicalTrials.gov with Granular Therapeutics Limited as lead sponsor.

NCT NCT07181369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07181369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Tolerability, Pharmacokinetic, Pharmacodynamic, and Preliminary Efficacy Trial of GTX-B001 in Healthy Volunteers (Part A) and Patients With Chronic Inducible Urticaria (Part B)
Lead sponsor
Granular Therapeutics Limited
Phase
Phase 1
Overall status
Recruiting
Start date
October 6, 2025
Completion date
August 31, 2027
Enrollment
72 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inducible urticaria, cold urticaria, healthy subjects, symptomatic dermographism